Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
23.09
+1.20 (5.48%)
At close: Feb 2, 2026, 4:00 PM EST
23.09
0.00 (0.00%)
After-hours: Feb 2, 2026, 4:32 PM EST
Capricor Therapeutics Employees
Capricor Therapeutics had 160 employees as of December 31, 2024. The number of employees increased by 58 or 56.86% compared to the previous year.
Employees
160
Change (1Y)
58
Growth (1Y)
56.86%
Revenue / Employee
$69,566
Profits / Employee
-$512,435
Market Cap
1.19B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 160 | 58 | 56.86% | 160 | 0 |
| Dec 31, 2023 | 102 | 28 | 37.84% | 101 | 1 |
| Dec 31, 2022 | 74 | 26 | 54.17% | 74 | 0 |
| Dec 31, 2021 | 48 | 22 | 84.62% | 48 | 0 |
| Dec 31, 2020 | 26 | 10 | 62.50% | 26 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AbCellera Biologics | 596 |
| Phathom Pharmaceuticals | 427 |
| Xeris Biopharma Holdings | 394 |
| Sana Biotechnology | 194 |
| Day One Biopharmaceuticals | 184 |
| EyePoint | 165 |
| Inhibrx Biosciences | 161 |
| MoonLake Immunotherapeutics | 100 |
CAPR News
- 6 weeks ago - Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript - Seeking Alpha
- 2 months ago - Capricor: Maintaining 'Hold' Rating On Randomized Phase 3 HOPE-3 Trial Win With Deramiocel - Seeking Alpha
- 2 months ago - Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy Transcript - Seeking Alpha
- 2 months ago - Capricor Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Capricor Stock Soars, Shkreli Is Short: Here's What Pharma Bro Had To Say - Benzinga
- 2 months ago - Capricor Therapeutics Duchenne Treatment Shows Strong Heart And Muscle Results In Trial - Benzinga
- 2 months ago - Capricor's muscle disorder cell therapy succeeds in late-stage study - Reuters
- 2 months ago - Martin Shkreli Takes Aim At Capricor — Stock Sinks - Benzinga